GSM5359414
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.570
- TNFA_SIGNALING_VIA_NFKB+0.410
- P53_PATHWAY+0.400
- HYPOXIA+0.390
- MTORC1_SIGNALING+0.380
- IL6_JAK_STAT3_SIGNALING+0.350
- INFLAMMATORY_RESPONSE+0.350
- ALLOGRAFT_REJECTION+0.340
- COAGULATION+0.300
- FATTY_ACID_METABOLISM+0.290
Top 10 suppressed
- MITOTIC_SPINDLE-0.090
- DNA_REPAIR-0.070
- UNFOLDED_PROTEIN_RESPONSE-0.050
- BILE_ACID_METABOLISM-0.030
- UV_RESPONSE_DN-0.030
- E2F_TARGETS+0.030
- SPERMATOGENESIS+0.040
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.050
- MYOGENESIS+0.050
- PROTEIN_SECRETION+0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313165 | — | E | 0.869 |
| 2 | EPT0508 | EPN | Posterior Fossa EPN | 0.863 |
| 3 | 20060039.TNBC | — | C | 0.858 |
| 4 | 0E9EAAED-A9A2-41E7-AC3A-49E94C933432 | — | — | 0.853 |
| 5 | TCGA-BT-A0YX-01A-11R-A10U-07 | — | — | 0.851 |
| 6 | MDT-AP-2149 | Med | Medulloblastoma | 0.849 |
| 7 | TCGA-C8-A26X-01A-31R-A16F-07 | — | C | 0.848 |
| 8 | MNG919 | — | — | 0.848 |
| 9 | MDT-AP-2506 | Med | Medulloblastoma | 0.846 |
| 10 | C3L-02650 | — | cohortSQ1 | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.570 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.400 | Idelalisib | — uncovered |
| HYPOXIA | 0.390 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.270 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |